Upon completion of the activity, participants will learn:

1. Mechanism and Selectivity, participants will be able to learn the mechanism of action of Capivasertib as a selective AKT inhibitor and describe how its unique binding properties and selectivity profile differentiate it from other PI3K/AKT pathway inhibitors.
2. Clinical Evidence and Applications, participants will be able to learn the clinical efficacy and safety profile of Capivasertib based on key trial data, particularly in hormone receptor-positive breast cancer.
3. Treatment Integration and Future Directions, discussion will be made about how biomarker-driven patient selection can optimize treatment outcomes while considering the broader implications for precision oncology approaches.